Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition containing herbal medicine extracts of pinellia and scutellaria for reducing side effects due to anticancer drugs

a technology of anticancer drugs and herbal medicine, applied in the field of composition, can solve the problems of further increasing indigestion or compaction, reducing gastrin production, and gastrointestinal toxicities, and achieve excellent effect of reducing side effects, reducing side effects, and reducing side effects

Inactive Publication Date: 2016-04-28
COMPREHENSIVE & INTEGRATIVE MEDICINE INST
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is a composition that reduces side effects caused by an anticancer drug. It contains a blend of rare herbal ingredients, namely, a pinelliae rhizoma and scutellariae radix extract. This blend has antioxidant properties that help reduce damage to the gastrointestinal tract and improve gastrointestinal motility disorder. The composition also regulates gastrin and serotonin production in gastrointestinal endocrine cells, which helps to further alleviate the side effects of anticancer drugs. Overall, this invention provides a natural and effective way to minimize the side effects of anticancer drugs while maintaining their effectiveness in treating cancer.

Problems solved by technology

However, as serotonin is synthesized and serotonin 5-HT3 receptors are activated in endocrine cells present in the digestive tract, gastrointestinal motility as well as damage to the gastrointestinal tract are considerably inhibited, thereby causing a variety of toxicities in the gastrointestinal tract, for example, gastric stasis of food.
A gastrointestinal motility disorder, particularly, a decrease in gastrointestinal motility is caused by cisplatin, and as a result, gastrin production is considerably reduced, thereby further increasing indigestion or compaction.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition containing herbal medicine extracts of pinellia and scutellaria for reducing side effects due to anticancer drugs
  • Composition containing herbal medicine extracts of pinellia and scutellaria for reducing side effects due to anticancer drugs
  • Composition containing herbal medicine extracts of pinellia and scutellaria for reducing side effects due to anticancer drugs

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation and Method of Experiment

[0036]1.1. Preparation of Laboratory Animals

[0037]In this example, as laboratory animals, Sprague-Dawley, Slc: SD rats (6-week-old males, SLC, Shizuoka, Japan) were used. 60 healthy SPF rats were purchased, acclimated for 14 days, and 8 laboratory animals having uniform body weights (intact control: 249.13±12.12 g, 232˜264 g; cisplatin treated group: 225.35±10.58 g, 206˜243 g) when fasting after three weeks of cisplatin administration per each group were selected to be used in the experiment. As shown in Table 2, the laboratory animals were divided into 6 groups. All of the laboratory animals underwent fasting for about 18 hours at each of the first treatment of cisplatin, the first drug administration and the final necropsy (even in this period, drinking water was freely provided), individuals were identified using picric acid.

[0038]To cause a gastrointestinal motility disorder, 2 mg / kg of cisplatin (Sigma-Aldrich, St. Louise, Mo., USA) was disso...

example 2

Confirmation of Changes in Body Weight and Body Weight Gain

[0042]Body weights and body weight gains in each group that were measured after the first and fourth administrations of cisplatin and the necropsy are shown in Table 3.

TABLE 3Body weight (g)At firstAt 4thBody weight gain (g)cisplatincisplatinTotal experimentTest article dosingGroupstreatment [A]treatment [B]Sacrifice [C]periods [C-A]periods [C-B]ControlsIntact198.38 ± 12.82249.13 ± 12.12 252.88 ± 13.5154.50 ± 5.13   3.75 ± 2.87Cisplatin199.13 ± 14.12225.00 ± 13.90a195.13 ± 12.96a−4.00 ± 7.01 d −29.88 ± 3.04dReferenceOndansetron197.88 ± 11.37226.88 ± 6.60a 212.38 ± 4.66ab14.50 ± 11.64de−14.50 ± 5.68dePS orally administered200 mg / kg199.13 ± 12.02223.63 ± 12.28a231.75 ± 12.89ab32.63 ± 10.27de 8.13 ± 8.22e100 mg / kg199.38 ± 10.46226.38 ± 11.29a218.50 ± 6.89ab19.13 ± 6.62de  −7.88 ± 6.40de 50 mg / kg198.25 ± 15.07224.88 ± 10.08a212.00 ± 8.78ac13.75 ± 13.12df −12.88 ± 9.58de

[0043]Three weeks after the first cisplatin administration, ...

example 3

Confirmation of Change in Charcoal Transit Ratio in Small Intestine (Gastrointestinal Motility)

[0047]In a digestive motility disorder, due to reduction in fecal excretion such as constipation and excessive water absorption caused by related fecal retention, it is known that water content in feces is considerably decreased, and fecal parameters such as a fecal pellet number and the water content in the feces have been used to evaluate effects of various drugs on the digestive motility disorder. Also, permeation of a substance through the digestive tract represents the motility in the entire gastrointestinal tract, measurement of a charcoal transit ratio in the small intestine is known to be very useful to diagnose whether or not there is a problem in digestive motility (Wintola et al., 2010), and a decrease in the charcoal transit ratio in the small intestine indicates a decrease in digestive motility such as the fecal retention, that is, constipation (Sagar et al., 2005; Meite et al...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a composition containing a Pinelliae Rhizoma and Scutellariae Radix extract as an active ingredient to reduce side effects caused by an anticancer drug, and more particularly, a composition for reducing side effects such as damage to the gastrointestinal tract and a gastrointestinal motility disorder by administering an anticancer drug. The composition of the present invention has an excellent effect of reducing side effects in administration of the anticancer drug through an antioxidative function, and synthesis, secretion and control of the functions of gastrin and serotonin producing gastrointestinal endocrine cells.

Description

TECHNICAL FIELD[0001]The present invention relates to a composition containing a Pinelliae Rhizoma and Scutellariae Radix extract as an active ingredient to reduce side effects caused by an anticancer agent.BACKGROUND ART[0002]Cisplatin is a representative platinum-complex anticancer drug containing platinum II in its center and a widely-used chemotherapeutic agent to treat a variety of tumors, and has shown a relatively excellent anticancer effect. However, as serotonin is synthesized and serotonin 5-HT3 receptors are activated in endocrine cells present in the digestive tract, gastrointestinal motility as well as damage to the gastrointestinal tract are considerably inhibited, thereby causing a variety of toxicities in the gastrointestinal tract, for example, gastric stasis of food. Particularly, cisplatin serves as a representative redox cycler producing active oxygen species (Chirino and Pedraza-Chaverri, 2009) to cause damage to the function and DNA of gastrointestinal mucosal ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K36/8888A61K36/539
CPCA61K36/539A61K36/8888A61P35/00A61K2300/00
Inventor RYU, HEON MOKIM, DAE JUNBYUN, JOON SEOKSOHN, KI CHEULKU, SAE KWANG
Owner COMPREHENSIVE & INTEGRATIVE MEDICINE INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com